Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04206878
Other study ID # EG0206
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2017
Est. completion date December 31, 2020

Study information

Verified date February 2021
Source Elizabeth Glaser Pediatric AIDS Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to assess the feasibility and utility of birth testing using point-of-care (POC) testing in maternity settings in Eswatini.


Description:

This UNITAID-funded study aims to assess feasibility and utility of birth testing, [early infant diagnosis for HIV, (EID)], using point-of-care (POC) HIV nucleic acid testing (NAT) at high volume maternity settings. Birth testing is defined as tests within 3 days of life. Outcome measures will include age at testing, turnaround time from testing to caregiver result receipt, HIV positivity rate, and timing of anti-retroviral therapy (ART) initiation for HIV-positive infants. The study will document retention in care for those who tested positive at birth, and the percent of those who tested negative at birth who returned for six week testing. The study will also assess the feasibility and acceptability of POC birth testing using interviews with policymakers, health care workers and caregivers of HIV-exposed infants (HEI).


Recruitment information / eligibility

Status Completed
Enrollment 3316
Est. completion date December 31, 2020
Est. primary completion date July 3, 2020
Accepts healthy volunteers
Gender All
Age group N/A to 4 Days
Eligibility Inclusion Criteria: - HIV Exposed Infants - Must have been newly born at the study sites or presenting in study sites within 3 days after birth - Tested for HIV using POC EID platform (mother or caregiver agreed to have infant tested) - Health Care Workers (HCWs) - HCWs who have used POC EID for at least three months, at project sites - HCWs that work directly with POC EID services at maternity providing clinical services or operating the platform - HCWs who consent to be interviewed - HCWs able to speak one of the study languages - Laboratory Managers and program leads/focal persons: - National or regional level manager or head of department whose responsibilities include EID - Member of a national technical working group or advisory board member working on EID - National level representative from the MOH - Laboratory managers in the 3 study sites - Participants 18 years and above who consent to be interviewed - Mothers/caregivers: - Mother/caregiver of an HEI who was offered POC EID at birth - Provides consent to participate in the study - Is 18 years or older, or is less than 18 years old but is legally married (and thus legally emancipated) - Speaks one of the study languages Exclusion Criteria: - HEIs: - HEI tested for HIV using conventional EID at projects sites - HEI whose caregivers refuse birth testing - HEI where the clinician deems there is a contra-indication for sample collection for birth testing (e.g. severe hemophilia) - HCWs: - HCWs who work within project sites that do not make use of EID (i.e. HCWs who are not involved directly with EID) - HCWs working in non-project sites - HCWs who are unable to consent or do not speak a study language - Laboratory Managers and program leads/focal persons: - Inability to give consent - Inability to speak study language - Mothers/Caregivers: - Not eligible for POC birth testing services - Not able to consent - Does not speak English or SiSwati

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Point-of-care birth test
Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers

Locations

Country Name City State
Swaziland Mbabane Government Hospital, Hlathikhulu Hospital, and Good Shepherd Hospital Mbabane

Sponsors (2)

Lead Sponsor Collaborator
Elizabeth Glaser Pediatric AIDS Foundation UNITAID

Country where clinical trial is conducted

Swaziland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of eligible HEI born at or presenting to pilot facilities who receive POC EID testing at birth Number of eligible HEI born at or presenting to pilot facilities receiving POC EID testing as a proportion of the number of HEI born or presenting to pilot facilities 24 months
Secondary Percent of tested HEI whose caregivers receive results of the POC EID birth testing Number of tested HEI whose caregivers receive results of the POC EID birth testing as a proportion of the number of tested HEI 24 months
Secondary HIV positivity rate among HEI tested at birth Number of HEI testing HIV positive at birth as a proportion of the number of HEI tested at birth 24 months
Secondary Number of HIV-infected infants (HII) tested at birth who are started on ART within 2 weeks of the birth test Number of HII tested at birth started on ART within 2 weeks as a proportion of the number of HII tested at birth 24 months
Secondary Percent of HEI testing HIV negative at birth who return for testing at 6-8 weeks Number of HEI testing HIV negative at birth who return for testing at 6-8 weeks as a proportion of the number of HEI testing HIV negative at birth 24 months
Secondary Percent of HEI who test HIV negative at birth and who test positive at 6-8 weeks Number of HEI who test HIV negative at birth and who test HIV positive at 6-8 weeks as a proportion of the number of HEI who test HIV negative at birth 24 months
Secondary Percent of HII testing HIV positive at birth or at 6-8 weeks in care for the first 3 and/or 6 months of life The number of HII testing HIV positive at birth or at 6-8 weeks in care for the first and/or 6 months of life as a proportion of the number of HII testing HIV positive at birth or at 6-8 week of life 24 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2